Forget Mounjaro: Eli Lilly's Next Big Blockbuster Has Arrived

Eli Lilly has a lot going for it.Over the last couple of years, the pharmaceutical industry has been taken over by glucagon-like peptide-1 (GLP-1) agonists. Even if you aren't familiar with that terminology, I'd wager that you're well aware of diabetes and obesity medications such as Ozempic, Wegovy, and Mounjaro -- which are all GLP-1 drugs.For now, Denmark-based Novo Nordisk (NVO -1.58%) dominates the GLP-1 market, thanks to its deep roster of treatments including Ozempic, Wegovy, Rybelsus, and Saxenda. H ...